Anti-4-1BBL [AT113-2]

Absolute Antibody

Anti-4-1BBL [AT113-2]

7

This antibody has been used in various FACS analyses, for instance, to show that CD27:CD70 and 4-1BB:4-1BBL interactions are needed for dendritic cell-driven accumulation of antitumor cytotoxic T lymphocytes following anti-CD40 mAb treatment (French et al, 2007), to examine the underlying mechanisms of the differential T cell costimulation dependence in viral infections (Welten et al, 2015), and to explore the therapeutic benefit of using combinations of syngeneic tumor vaccines that express immune modulators (Manrique-Rincon et al, 2017). This antibody has been used as a blocking antibody, together with anti-CD70, anti-CD30L and anti-OX40L antibodies, to evaluate OX40 ligand and CD70 in the promotion of CD4+ T cell responses (Kurche et al, 2010). Furthermore, this anti-4-1BBL antibody has been used alongside the anti-CD70, anti-CD27, anti-CD40 antibodies in a BCL1-bearing mouse model to evaluate the theurapeutic potency of various combined immmunotherapies against lymphoma (French et al, 2007).

Flow Cytometry, Western Blot, Neutralisation/Blocking

FC; WB; blocking

Research Use Only

Tumor necrosis factor ligand superfamily member 9

This chimeric mouse antibody was made using the variable domain sequences of the original Rat IgG1 format, for improved compatibility with existing reagents, assays and techniques.

-20°C,2°C to 8°C

12352203